Sold out
LOAD MORE
You're viewed all 17 products
Posaconazole
References
FAQ's
References
- Saksena, Anil K.; Girijavallabhan, Viyyoor M.; Lovey, Raymond G.; Pike, Russell E.; Wang, Haiyan; Liu, Yi-Tsung; Ganguly, Ashit K.; Bennett, Frank “Tetrahydrofuran Antifungals” Schering Corp., United States, EP736030B1, December, 20, 1994.
- Feng, W.; Liu, H.; Chen, G.; Malchow, R.; Bennett, F.; Lin, E.; Pramanik, B.; Chan, T.-M., “Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS”, Journal of Pharmaceutical and Biomedical Analysis, Volume: 25, Issue: 3-4, Pages: 545-557, 2001
Frequently Asked Questions
What are the sources of Posaconazole impurities?
Posaconazole impurities originate from various sources, including starting materials, synthetic intermediates, and degradation products.
What are the common Posaconazole impurities found in the drug?
The common impurities found in Posaconazole include isomers, related compounds, and degradation products.
What is the significance of isomeric impurities in Posaconazole?
Isomeric impurities in Posaconazole can affect the potency and bioavailability of the drug.
How can the formation of Posaconazole impurities be prevented?
Prevent the formation of Posaconazole impurities by optimizing the synthetic process, controlling reaction conditions, and using appropriate analytical methods to monitor them.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.
